Thousands of Norwegians incorrectly informed of big lottery wins
July 1 (UPI) -- The national lottery operator in Norway apologized after at least 47,000 people who won small amounts were mistakenly told they had won much more.
Norsk Tipping sent a text message to 47,000 lottery players in the country informing them that their reported prize amounts for the Eurojackpot drawing had been mistakenly inflated due to an error in currency conversion.
The operator explained the prize amounts it receives from Germany are given in euros, which are then converted to Norwegian kroner. The error occurred during conversion for the recent Eurojackpot drawing, when the number of euros was multiplied by 100, instead of being divided.
Ole Fredrik Sveen, 53, one of the players who received the correction, said he was initially told he had won 1.2 million kroner -- about $119,010 -- but later learned his prize was only 125 kroner, or $12.40.
"You could have been really unlucky and spent a large amount of money then found out it wasn't true," Sveen told The Guardian. "But thankfully we kept our heads cool and realized it wasn't meant to be this time either."
Norsk Tipping apologized for the error, saying none of the incorrect prize amounts had been paid out.
"Norsk Tipping sincerely apologizes to everyone who was notified of an incorrect prize amount," the company said in a statement.
Norsk Tipping CEO Tonje Sagstuen apologized in a separate statement issued Saturday.
"I am terribly sorry that we have disappointed so many, and I understand that people are angry with us," Sagstuen said. "I have received many messages from people who had managed to make plans for holidays, buying an apartment or renovating before they realized that the amount was wrong."
Sagstuen has since stepped down as CEO, and was replaced by acting CEO Vegar Strand.
"We deeply regret what has happened, and on behalf of us at Norsk Tipping I would like to apologize to everyone who was affected by this," Strand said in a statement after taking up the position.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
an hour ago
- UPI
ADP: Private sector jobs unexpectedly fall by 33,000 in June
Private payroll processor ADP on Wednesday reported that private employers lost 33,000 jobs in June, far off expectations that the private sector would add 100,000 jobs. File Photo by Jim Ruymen/UPI | License Photo July 2 (UPI) -- Private payrolls declined in June, far off analysts' expectations that they would grow, according to data released by private payroll processor ADP on Wednesday. U.S. private employers lost 33,000 jobs in June, the first time private jobs declined since March 2023, the monthly report said. "Though layoffs continue to be rare, a hesitancy to hire and a reluctance to replace departing workers led to job losses last month," said ADP's Chief Economist and ESG Officer Dr. Nela Richardson. "Still, the slowdown in hiring has yet to disrupt pay growth." The decline surprised Dow Jones economists who had predicted a growth of 100,000 jobs. Service-providing jobs led the decline, with a net loss of 66,000 jobs led by declines of 56,000 professional/business services jobs and 52,000 in education/health services along with a decline of 14,000 jobs in financial activities. The losses offset growth of 32,000 jobs in the goods-producing sector with natural resources/mining, construction and manufacturing all adding new jobs. ADP also examined its client payrolls and determined that annual pay has risen 4.4% year-over-year, based on "actual, anonymized payroll data of more than 25 million U.S. employees." The APD research also indicates smaller companies lost more jobs than midsize or larger ones, with the largest establishments actually gaining 30,000 jobs while those with fewer than 20 employees lost 29,000.
Miami Herald
2 hours ago
- Miami Herald
South Korea to explore potential of Northern Sea Route
SEOUL, July 1 (UPI) -- South Korea is exploring the potential of the Arctic shipping routes, particularly the Northern Sea Route, which is expected to reduce shipping times and costs between Asia and Europe. The state-run Busan Port Authority noted Tuesday that it has established a dedicated team to prepare for the commercial use of the Arctic route. The newly structured team is projected to lead the strategic development of Arctic route initiatives and oversee related policies from planning to implementation, according to the BPA. "To address pressing challenges of Busan Port, including the Arctic Sea Route, a swift and flexible execution-oriented organization is essential," BPA President Song Sang-Keun said in a statement. The measure is in line with the policy direction of new President Lee Jae Myung. Lee is a strong proponent of Arctic shipping. During a presidential rally in May, he stressed the need to stay competitive with neighboring countries, including China and Japan. Lee was elected to become the nation's 21st president by winning the June 3 by-election, which took place due to the impeachment of his predecessor Yoon Suk-yeol. Yoon was ousted from the post after his controversial martial decree declaration late last year. Global warming is credited for opening the Northern Sea Route, which is expected to become commercially viable in the 2030s. If a vessel departs from Busan Port, around 200 miles southeast of Seoul, and travels to Rotterdam in the Netherlands via the Suez Canal, the total distance is about 12,400 miles, However, using the Northern Sea Route shortens the distance to some 8,700 miles. In his recent book, Seoul National University honorary professor Kim Tai-yoo wrote that the Northern Sea Route offers significant growth potential for South Korea. "If South Korea can take the lead in forming a strategic alignment among the U.S., Russia, and itself -- securing early access to the Arctic route and establishing key port hubs -- it could position itself at the very core of the new global order the United States seeks to build," Kim wrote. Copyright 2025 UPI News Corporation. All Rights Reserved.
CNBC
4 hours ago
- CNBC
London stock market could weather its biggest blow yet if AstraZeneca exits
Pressure is piling on London's stock exchange, with reports that British pharma giant AstraZeneca may move its listing to the U.S. delivering yet another blow this week. CEO Pascal Soriot is considering moving the company's stock listing from London to the U.S., British newspaper The Times reported on Tuesday afternoon, citing anonymous sources. Soriot's frustrations with the U.K.'s regulatory environment — particularly rules around new medicine approvals and drug pricing systems — are said to be driving the move. AstraZeneca declined to comment on the Times report. The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable business listed on London's FTSE 100. AstraZeneca's market cap was £161.2 billion ($221.1 billion) as of Tuesday's closing price, according to LSEG data. AstraZeneca's potential transatlantic move would add to concerns around London's weakening status as a global financial hub. A number of companies have delisted from the London market or reconsidered plans to float shares in the city over the past year. Toni Meadows, head of investment at London's BRI Wealth Management, labeled AstraZeneca's rumored listing considerations as "disappointing" for the U.K. equity market — but he conceded that "it is not surprising" given that it would form the latest development in a wider established trend. Earlier this year, reports emerged that Chinese fast fashion giant Shein was looking to list in Hong Kong instead of London, when it goes public. Last week, news agency Reuters reported that the company was planning to file confidentially for a Hong Kong IPO. Metals investor Cobalt Holdings, meanwhile, confirmed to CNBC last month that it had scrapped plans for a London IPO, while British fintech giant Wise announced in June that it was moving its primary listing from London to New York. Kristo Kaarmann, Wise's CEO and co-founder, said in a statement at the time that the move would help raise awareness of the company in the U.S., while giving the firm better access to "the world's deepest and most liquid capital market." Companies listed in London have historically had much lower valuations than their Wall Street counterparts. Research from British investment manager Rathbones last year showed that the forward price-to-earnings ratio for U.K. stocks was 32% lower than those listed in the U.S. on a like-for-like basis. On the flipside, the Financial Times reported last week that Norwegian software giant Visma had chosen London for its upcoming debut on the public market. "Large and important companies like AstraZeneca are seeking a valuation uplift from exposure to a wider investor base and they will get that from moving to a US listing," BRI's Meadows told CNBC via email on Wednesday. "The trend to move listing, or the stream of takeovers for UK listed stocks, highlights value in the UK equity market, but it does nothing to encourage a new supply of companies listing here to support the future standing of the index in a Global context," Meadows added. Claire Trachet, founder of M&A advisory Trachet, said AstraZeneca shifting its listing to New York would represent "a memorable loss" for the London Stock Exchange. "Given the complexity of the company, this isn't simply because of liquidity or valuation advantages often cited by departing firms, rather a trifecta of underperforming capital markets, regulatory constraints, and misaligned incentives that make it harder to scale and reward innovation at home," she told CNBC by email. Trachet added that London-listed companies with a combined value in excess of $100 billion had already made the move to New York in recent years — and AstraZeneca's departure alone would more than double that figure. "The potential move makes it painfully clear to global markets that the UK is losing its edge on the needs of world-class, scale-driven companies," she said. "This isn't an isolated story — and that's the biggest issue. It's part of a broader shift, where founders and boards are increasingly looking to the US for deeper capital, stronger support, and a more ambitious investor base." Tom Bacon, a London-based partner at global law firm BCLP — which has a division dedicated to M&A and corporate finance — labeled reports of AstraZeneca's Soriot's desire to shift away from London "very worrying." "I think this should sound the alarm for the UK government that they need to do more both to support the city and our stock market together with our critical industries like life sciences and pharmaceuticals," he said. Dan Coatsworth, investment analyst at AJ Bell, on Wednesday said that AstraZeneca's reported plans appeared to be driven by business needs rather than chasing a higher valuation — but he added that moving the company's listing across the Atlantic "won't be an easy move to pull off." "Unlike many other UK market 'defectors' with a dominant US shareholder base like CRH and Flutter, AstraZeneca has a more geographically diverse pool of investors," he explained in an email. However, Coatsworth noted that AstraZeneca generates around 42% of its sales from the U.S., and already has plans to increase its operational footprint in the country. Earlier this year, CEO Soriot told CNBC AstraZeneca was "very committed to the United States," where the company has two large research and development centers. AJ Bell's Coatsworth told CNBC that AstraZeneca's CEO could also see a full U.S. stock listing as a "stepping stone to receiving better treatment Stateside." European pharmaceutical companies are facing uncertainty around their future in the American market, where U.S. President Donald Trump has threatened to impose sector-specific tariffs on drug imports. While the industry was exempted from Trump's so-called reciprocal tariffs plans when they were unveiled in April, the White House leader has since placed the sector under investigation by the U.S. Commerce Department, warned tariffs on pharma are "coming soon," and signed an executive order directing medicine manufacturers to lower the price of some drugs in line with costs paid overseas.
